Scientist-inventors from ORNL will present seven new technologies during the Technology Innovation Showcase on Friday, July 14, from 8 a.m.–4 p.m. at the Joint Institute for Computational Sciences on ORNL’s campus.
Seven scientists at the Department of Energy’s Oak Ridge National Laboratory have been named Battelle Distinguished Inventors, in recognition of their obtaining 14 or more patents during their careers at the lab.
Laboratory Director Thomas Zacharia presented five Director’s Awards during Saturday night's annual Awards Night event hosted by UT-Battelle, which manages ORNL for the Department of Energy.
Marc-Antoni Racing has licensed a collection of patented energy storage technologies developed at ORNL. The technologies focus on components that enable fast-charging, energy-dense batteries for electric and hybrid vehicles and grid storage.
ORNL scientists will present new technologies available for licensing during the annual Technology Innovation Showcase. The event is 9 a.m. to 3 p.m. Thursday, June 16, at the Manufacturing Demonstration Facility at ORNL’s Hardin Valley campus.
ORNL, TVA and TNECD were recognized by the Federal Laboratory Consortium for their impactful partnership that resulted in a record $2.3 billion investment by Ultium Cells, a General Motors and LG Energy Solution joint venture, to build a battery cell manufacturing plant in Spring Hill, Tennessee.
Three ORNL scientists have been elected fellows of the American Association for the Advancement of Science, or AAAS, the world’s largest general scientific society and publisher of the Science family of journals.
A world-leading researcher in solid electrolytes and sophisticated electron microscopy methods received Oak Ridge National Laboratory’s top science honor today for her work in developing new materials for batteries. The announcement was made during a livestreamed Director’s Awards event hosted by ORNL Director Thomas Zacharia.
A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.
Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.